Health & Fitness
Thu, January 19, 2012Wed, January 18, 2012Tue, January 17, 2012Mon, January 16, 2012Fri, January 13, 2012Thu, January 12, 2012Wed, January 11, 2012Tue, January 10, 2012Mon, January 9, 2012Sun, January 8, 2012Sat, January 7, 2012Fri, January 6, 2012Thu, January 5, 2012Wed, January 4, 2012Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. -- Competition in Generic Drugs Heating Up
//health-fitness.news-articles.net/content/2012/ .. inc-competition-in-generic-drugs-heating-up.html
Published in Health and Fitness on Wednesday, January 11th 2012 at 5:09 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
January 11, 2012 08:00 ET
Equity Research on Mylan Inc. and Watson Pharmaceuticals Inc. -- Competition in Generic Drugs Heating Up
NEW YORK, NY--(Marketwire - Jan 11, 2012) - [ www.shinesrooms.com ] has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Drugs - Generic industry and are offering free analytical research on Mylan Inc. (
Companies in the Drugs - Generic industry, such as Mylan Inc. and Watson Pharmaceuticals Inc., have been performing well recently. A number of blockbuster patents have already expired and with more to come in 2012, the industry could be well positioned moving forward. Get your free reports on Mylan Inc. and Watson Pharmaceuticals Inc. at [ http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index ]. There is no commitment to join.
[ www.shinesrooms.com ] is the Ultimate Trading Environment for investors. If you are considering owning Mylan Inc. and Watson Pharmaceuticals Inc. then you should sign up for a free membership and our complimentary reports today at [ www.shinesrooms.com ]. Over the last 5 years our returns outpaced any of the major indexes. Sign up today to find out what you are missing.
Being the first to file abbreviated new drug applications (ANDAs) is important for generic drug companies, as those that can secure 180 day exclusivity rights are able to get a jump on other generic makers. Mylan has recently received FDA approval to launch generic versions of a number of products, and has a strong pipeline of ANDAs pending. Mylan Inc. report is accessible for free by registering today at [ http://www.shinesrooms.com/Mylan Inc110112.pdf ].
While patent expiries and approved ANDAs are positives for companies in the industry, increased competition from generic as well as branded drug companies could make things interesting. Some branded companies are looking to recoup losses from patent expiries by offering their own generic versions of popular products. How this will play out in 2012 remains to be seen; however, the industry should be an exciting one to follow as the year progresses. Watson Pharmaceuticals Inc. report is accessible for free by registering today at [ http://www.shinesrooms.com/WatsonPharmaceuticalsInc110112.pdf ].
The two Drugs - Generic stocks research reports are available for free by signing up now on [ www.shinesrooms.com ].
About Shinesrooms.com
Shine's Rooms is the brainchild of David Shine, a 13-year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting-edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.
To view our disclaimer, visit this link [ http://www.shinesrooms.com/disclaimer.html ].
